ATE61228T1 - Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. - Google Patents

Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.

Info

Publication number
ATE61228T1
ATE61228T1 AT83850273T AT83850273T ATE61228T1 AT E61228 T1 ATE61228 T1 AT E61228T1 AT 83850273 T AT83850273 T AT 83850273T AT 83850273 T AT83850273 T AT 83850273T AT E61228 T1 ATE61228 T1 AT E61228T1
Authority
AT
Austria
Prior art keywords
complex
vaccine
production
immunogenic protein
immune stimulant
Prior art date
Application number
AT83850273T
Other languages
English (en)
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein filed Critical Bror Morein
Application granted granted Critical
Publication of ATE61228T1 publication Critical patent/ATE61228T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT83850273T 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. ATE61228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP83850273A EP0109942B1 (de) 1982-10-18 1983-10-13 Immunogener Protein- oder Peptidkomplex, Verfahren zur Herstellung dieses Komplexes und seine Verwendung als Immunstimulans und als Impfstoff

Publications (1)

Publication Number Publication Date
ATE61228T1 true ATE61228T1 (de) 1991-03-15

Family

ID=20348235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83850273T ATE61228T1 (de) 1982-10-18 1983-10-13 Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.

Country Status (18)

Country Link
US (2) US4578269A (de)
EP (1) EP0109942B1 (de)
JP (1) JPH07112983B2 (de)
AR (1) AR243080A1 (de)
AT (1) ATE61228T1 (de)
AU (1) AU558258B2 (de)
CA (1) CA1243954A (de)
DE (2) DE3382190D1 (de)
DK (1) DK162057C (de)
ES (1) ES8503951A1 (de)
FI (1) FI80600C (de)
IE (1) IE57025B1 (de)
MX (1) MX7563E (de)
NO (1) NO163668C (de)
NZ (1) NZ205925A (de)
PT (1) PT77515B (de)
SE (1) SE8205892D0 (de)
ZA (1) ZA837603B (de)

Families Citing this family (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
SE8402861L (sv) * 1984-05-28 1985-11-29 Stefan Svenson Rening av biologiskt material
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
ZA872203B (en) * 1986-04-28 1988-02-24 New York Blood Center Inc Complex immunogen containing synthetic peptides
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
WO1989005151A1 (en) * 1987-12-04 1989-06-15 The Liposome Company, Inc. High integrity liposomes and method of preration and use
WO1989006658A1 (en) * 1988-01-13 1989-07-27 The University Of North Carolina At Chapel Hill Immunogenic peptides
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
DK199588D0 (da) * 1988-04-12 1988-04-12 Nordisk Droge & Kemikalie Vaccine
AU638210B2 (en) * 1988-05-04 1993-06-24 Dana-Farber Cancer Institute, Inc. Protein micelles
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US6291228B1 (en) * 1988-08-03 2001-09-18 Vericore Limited Vaccine
GB8818415D0 (en) * 1988-08-03 1988-09-07 Animal Health Inst Vaccine
JPH0292996A (ja) * 1988-09-30 1990-04-03 Bror Morein アジュバントおよび脂質を含む複合体
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
AU639719B2 (en) * 1989-09-15 1993-08-05 Tanox Biosystems, Inc. Treatment of autoimmune disease
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE4220653A1 (de) * 1992-06-26 1994-01-13 Boehringer Mannheim Gmbh Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
EP0604727A1 (de) * 1992-12-31 1994-07-06 American Cyanamid Company Verbesserte Immunogenizität einer Vakzine durch Inkorporieren eines Zytokines in einen immun-stimulierenden Komplex, der ein Antigen enthält
EP0716697B1 (de) * 1993-09-03 2003-04-02 McGILL UNIVERSITY Differentiell exprimierte leishmania gene und proteinen
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996015807A1 (en) * 1994-11-21 1996-05-30 Scofield Virginia L Sperm as vaccine vectors
CA2211650A1 (en) * 1995-01-27 1996-08-01 Genencor International, Inc. Surfactant-based extraction process
DE69521533T2 (de) * 1995-06-07 2001-10-04 Pfizer In ovo impfung gegen coccidiose
SK282004B6 (sk) 1995-06-07 2001-10-08 Pfizer Inc. Použitie živých sporozoitov alebo merozoitov rodu eimeria na výrobu očkovacej látky na in ovo očkovanie domestikovaných vtákov proti kokcidióze
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
GB9618119D0 (en) * 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
ZA9710606B (en) * 1996-12-05 1998-06-12 Akzo Nobel Nv Non-virulent Mycoplasma synoviae vaccine thereof.
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6495140B1 (en) 1998-01-12 2002-12-17 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for the isolation, recovery and purification of non-polar extractives
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
AU783344B2 (en) * 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DE60036952T2 (de) * 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
WO2001070247A2 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
WO2001077365A2 (en) 2000-04-06 2001-10-18 Pharmacia & Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
ES2392943T3 (es) 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Vacunas antitumorales
JP2004511527A (ja) * 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
EP2269639B1 (de) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza Vakzinzusammensetzungen zur intradermaler Verabreichung
NZ529347A (en) 2001-04-04 2008-01-31 Nordic Vaccine Technology As Use of at least one sterol capable of interacting with a nucleic acid and at least saponin to form immunostimulating complexes ( IMSCO )
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CN101381681B (zh) 2001-08-30 2013-08-07 恩布里克斯公司 制备卵囊的改进方法
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
JP2005535350A (ja) 2002-08-12 2005-11-24 アクゾ・ノベル・エヌ・ベー ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7125425B2 (en) * 2002-10-21 2006-10-24 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
WO2004045641A2 (en) 2002-11-20 2004-06-03 Crucell Holland B.V. Antigen-complexes
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BRPI0415025A (pt) 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
WO2005117958A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
EP3312272B1 (de) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation der replikationsrate durch verwendung von seltener verwendeten synonymen kodonen
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK1838341T3 (da) 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
JP2008546658A (ja) 2005-06-16 2008-12-25 ウニヴァシテイト ゲント ヘリコバクターに対する免疫化のためのワクチン
AU2006273753B2 (en) 2005-07-28 2010-06-24 Zoetis Services Llc Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
JP4667507B2 (ja) 2005-10-07 2011-04-13 ファイザー・プロダクツ・インク イヌインフルエンザを治療するワクチンおよび方法
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PT1962899E (pt) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Vacina conjugada polissacarídica pneumocócica
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3753574A1 (de) 2006-01-27 2020-12-23 Seqirus UK Limited Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
EP2010537B1 (de) 2006-03-23 2011-12-28 Novartis AG Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EA020459B1 (ru) 2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008001224A2 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
EA200900033A1 (ru) 2006-07-18 2009-12-30 Глаксосмитклайн Байолоджикалс С.А. Вакцины против малярии
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EP2064230A2 (de) 2006-08-16 2009-06-03 Novartis AG Immungene aus uropathogenen escherichia coli
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
ES2660035T3 (es) 2006-12-27 2018-03-20 Zoetis Services Llc Procedimiento de administración de vacuna
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0811908A2 (pt) 2007-05-25 2014-11-18 Novartis Ag Antígenos de pilus de streptococcus pneumoniae
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101969992B (zh) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57突变型抗原和gas57抗体
EP2062594A1 (de) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Impfstoff und immunogene Zusammensetzung gegen den Blauzungenvirus, Verfahren zu deren Verwendung und Verfahren zu deren Herstellung
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
CA2710600C (en) 2007-12-24 2017-06-06 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
CA2754618A1 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2510947B1 (de) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Zusammensetzungen zur Immunisierung gegen Staphylococcus aureus
EP3124491B1 (de) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen sowie pharmazeutische zusammensetzungen die diese enthalten
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
EA023054B1 (ru) 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
AU2010269148A1 (en) * 2009-07-10 2012-01-19 Isconova Ab New composition
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP2013507944A (ja) 2009-10-22 2013-03-07 ウニヴェルシテート・ライプツィヒ 汎血球減少症罹患仔ウシにおけるサーコウイルス（ｃｉｒｃｏｖｉｒｕｓ）の特定
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EP2560985B1 (de) 2010-04-21 2016-06-29 Pharmaq AS Nukleinsäuresequenzen eines fischvirus und ihre verwendung
RU2636455C2 (ru) 2010-05-14 2017-11-23 Баксалта Инкорпорейтид, (US) Химерные гены ospa, белки и способы их применения
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP4008313A1 (de) * 2010-06-24 2022-06-08 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur stabilisierung von proteinhaltigen formulierungen
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
CN103052401A (zh) 2010-07-23 2013-04-17 伊斯克诺瓦公司 流感疫苗
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012059592A1 (en) 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for delivering a therapeutic or imaging agent to the brain
CA2817933A1 (en) 2010-11-15 2012-05-24 Pharmaq As New salmon calicivirus isolate
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
AU2011340477A1 (en) 2010-12-08 2013-06-20 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (de) 2010-12-08 2012-06-13 Neovacs Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2658568A1 (de) 2010-12-29 2013-11-06 Intervet International B.V. Impfstoffantigen von babesiose des hundes
EP2658866B1 (de) 2010-12-29 2016-05-25 Intervet International B.V. Salmonid-alphavirusprotein e2
WO2012093706A1 (ja) * 2011-01-07 2012-07-12 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
EP4144368A1 (de) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
US20140086954A1 (en) 2011-03-31 2014-03-27 Chu De Toulouse Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
EP2508197A1 (de) 2011-04-07 2012-10-10 Neovacs Verfahren zur Behandlung IFN-alpha-assoziierter Erkrankungen
BR112013025892B1 (pt) 2011-04-07 2021-01-19 Neovacs produto imunogênico, forma de dosagem unitária, dispositivo médico e kit relacionados a ifna
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
CA2836098C (en) 2011-05-13 2022-06-21 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
AU2012306282A1 (en) 2011-09-08 2014-03-20 Umc Utrecht Holding B.V. Vaccine based on Staphylococcal superantigen-like 3 protein (SSL3)
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
AU2012319239B2 (en) 2011-10-03 2017-04-20 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
PL2782598T3 (pl) 2011-11-23 2021-03-08 In3Bio Ltd. Rekombinowane białka i ich zastosowania terapeutyczne
EP2785184B1 (de) 2011-11-30 2020-06-10 Emory University ZUSAMMENSETZUNGEN ENTHAlTEND JAK-HEMMER UND HAART-MEDIKAMENTE ZUR VORBEUGUNG ODER BEHANDLUNG VON HIV
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CN104582718B (zh) 2012-10-03 2017-10-24 诺华股份有限公司 免疫原性组合物
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
EP2968521A2 (de) 2013-03-15 2016-01-20 GlaxoSmithKline Biologicals S.A. Impfstoff
AU2014229561B2 (en) 2013-03-15 2018-06-07 Keith Alan Charlton Self-assembling synthetic proteins
CA2907571A1 (en) 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
SG11201600709TA (en) 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
EP3613430A2 (de) 2013-10-11 2020-02-26 Servizo Galego De Saúde (Sergas) Abgeschwächte lebendimpfstoffe
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
JP2017501162A (ja) 2013-12-16 2017-01-12 ゾエティス・サービシーズ・エルエルシー ヘンドラ及びニパウイルスｇ糖タンパク質免疫原性組成物
EP3915579A1 (de) 2013-12-31 2021-12-01 Infectious Disease Research Institute Impfstoffformulierungen mit einzelphiole
CA2942450A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
US10813984B2 (en) 2014-04-24 2020-10-27 Rhode Island Hospital Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
US9790509B2 (en) 2014-07-18 2017-10-17 Oregon Health & Science University 5′-triphosphate oligoribonucleotides
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
CN104250640A (zh) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
AU2015310932B2 (en) 2014-09-03 2018-11-22 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
BR112017006620B1 (pt) 2014-10-03 2023-12-26 Intervet International B.V Vacina, métodos para a preparação de uma vacina e para reduzir infecção por reovírus aviário, composição, e, usos de material antigênico e de uma vacina
CA2963437A1 (en) 2014-10-15 2016-04-21 Xenothera Composition with reduced immunogenicity
WO2016140702A1 (en) 2015-03-03 2016-09-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces Display platform from bacterial spore coat proteins
CN111560355A (zh) 2015-03-20 2020-08-21 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用
US10954492B2 (en) 2015-06-10 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
MX2018002728A (es) 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CN105770887A (zh) * 2016-03-04 2016-07-20 邓招红 一种用于hbv疫苗的佐剂及其制备方法
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CA3153265A1 (en) 2016-08-17 2018-02-22 Pharmaq As Sea lice vaccine
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
MX2020000636A (es) 2017-07-18 2020-08-20 In3Bio Ltd Proteinas sinteticas y usos terapeuticos de las mismas.
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
CA3092984A1 (en) 2018-03-19 2019-09-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
JP2021534761A (ja) 2018-08-23 2021-12-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性タンパク質および組成物
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
CA3144845A1 (en) 2019-06-25 2020-12-30 In3Bio Ltd. Stabilized chimeric synthetic proteins and therapeutic uses thereof
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3922255A1 (de) 2020-06-10 2021-12-15 Prokarium Limited Krebstherapie
IL303334A (en) 2020-12-02 2023-07-01 Glaxosmithkline Biologicals Sa The perfect fimh by a donor strand
CA3203043A1 (en) 2020-12-23 2022-06-30 Odile DUVAUX Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherap
EP4124342A1 (de) 2021-07-28 2023-02-01 Prokarium Limited Krebstherapie mit lebenden attenuierten bakterien
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
EP0047480B1 (de) * 1980-09-05 1986-02-05 Institut Armand Frappier Bildung eines Immunosoms, das ausschliesslich aus Virusantigenen, die auf einer künstlichen Membran rekonstruiert sind, hergestellt wird
EP0056249B1 (de) * 1981-01-09 1985-06-26 New York Blood Center, Inc. Synthetische antigene Zusammensetzung und Verfahren zu deren Herstellung
GB2093039B (en) * 1981-01-29 1984-06-06 Nat Res Dev Improvements relating to hepatitis b vaccine
EP0058021A3 (de) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmazeutische Präparate
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Also Published As

Publication number Publication date
CA1243954A (en) 1988-11-01
JPS59186921A (ja) 1984-10-23
NO163668B (no) 1990-03-26
ZA837603B (en) 1984-12-24
JPH07112983B2 (ja) 1995-12-06
FI833748A (fi) 1984-04-19
FI80600B (fi) 1990-03-30
IE832394L (en) 1984-04-18
ES526524A0 (es) 1985-04-01
DE3382190D1 (de) 1991-04-11
AU558258B2 (en) 1987-01-22
DK478383D0 (da) 1983-10-17
DE109942T1 (de) 1984-12-06
DK478383A (da) 1984-04-19
AU2010383A (en) 1984-05-03
US4578269A (en) 1986-03-25
PT77515B (en) 1986-04-16
EP0109942A2 (de) 1984-05-30
FI833748A0 (fi) 1983-10-14
US4744983A (en) 1988-05-17
EP0109942A3 (en) 1985-08-14
EP0109942B1 (de) 1991-03-06
NO163668C (no) 1990-07-04
FI80600C (fi) 1990-07-10
IE57025B1 (en) 1992-03-25
SE8205892D0 (sv) 1982-10-18
DK162057C (da) 1992-02-10
DK162057B (da) 1991-09-09
NO833769L (no) 1984-04-24
MX7563E (es) 1989-10-17
AR243080A1 (es) 1993-07-30
PT77515A (en) 1983-11-01
NZ205925A (en) 1987-10-30
ES8503951A1 (es) 1985-04-01

Similar Documents

Publication Publication Date Title
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
ES8305419A1 (es) Un peptido
DE3768833D1 (de) Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren.
ATE43635T1 (de) Verfahren zur herstellung von interferon und expressionsvektoren dafuer.
DE68907164D1 (de) Verfahren zur herstellung von allylacetat.
DE3750176T2 (de) Impfstoff und verfahren zur herstellung.
DE68915915T2 (de) Verfahren zur Herstellung von cyclischen Polysiloxanen.
DE68906948T2 (de) Verfahren zur herstellung von nitrilen oder oxiden.
DE3786832D1 (de) Verfahren zur herstellung von immunoglobulinzubereitungen fuer intravenoese injektion.
DE3765959D1 (de) Verfahren zur herstellung von alpha-sialon-pulver.
DE3782696D1 (de) Verfahren zur herstellung von verschiedenfarbigen festen puder-zubereitungen.
DE272502T1 (de) Verfahren zur herstellung von instantteigwaren.
AT372856B (de) Verfahren zur herstellung von humanem relaxin
DE68910771T2 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE68912734T2 (de) Verfahren zur Herstellung von Tetrafluoräthylen.
DE3870775D1 (de) Verfahren zur herstellung von kieselsaeuregelteilchen.
DE3768372D1 (de) Verfahren zur herstellung von aethylenoxid.
DE3786870D1 (de) Methode zur herstellung von proteinen.
AT364813B (de) Verfahren zur herstellung von alpha-aryl-alpha, alpha-di(omega-aminoalkyl)acetamiden mit disubstituierter aminogruppe
DE255178T1 (de) Verfahren zur herstellung von heteroaryl- und arylalkansaeuren.
DE3884324T2 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
DE3874445D1 (de) Verfahren zur herstellung von schalentierextrakt-konzentraten und schalentierextrakt-konzentrate.
DE68902379T2 (de) Verfahren zur herstellung von verbessertem proteinhydrolysat.
DE68912619T2 (de) Methode zur Erzeugung von Bildern.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time